## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

10/609.346

Confirmation No.: 1103

Applicant

Examiner

Yu et al June 26, 2003

Filed TC/A.U.

1646

Prema Maria Mertz

RECEIVED **CENTRAL FAX CENTER** 

MAR 1 9 2007

Old Docket No.:

ZYU-0603 118.01

New Docket No.: Customer No.:

27165

Mail Stop: AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

Pursuant to the duty of disclosure provisions of 37 C.F.R. 1.56, Applicants hereby submit an Information Statement in accordance with 37 C.F.R. 1.97 for the abovereferenced application, and a fee of \$180.00 in accordance with 37 C.F.R. 1.97(c)(2) and 1.17(p).

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

#### CERTIFICATE OF TRANSMISSION

I hereby certify that, on the date shown below, this correspondence is being facsimile transmitted to the Commissioner of Patents, at Fax No. (571) 273-8300.

Typed or printed name of person signing this certificate

03/19/2007 TL0111

09989931 10609346

01 FC:1806

189.00 OP

Mar. 18 2007 12:09PM P2

A PTO-SB-08A Form listing the references, along with copies of the references, is enclosed. Applicant respectfully requests that the Examiner consider the listed documents and indicated that they were considered by making appropriate notation on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If the Examiner applies any of the documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Respectfully submitted,

Date: 3/18/200)

Registration No. 44,211 Agent for Applicant

Please address all correspondence to:

Customer Number 27165

# **CENTRAL FAX CENTER**

### MAR 1 9 2007

PYO/SB/08B (07-05)
Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1446/PTO				Complete if Known			
				Application Number	10/609,346		
INFORMATION DISCLOSURE				Filing Date	June 26, 2003		
STA	TEMENT I	BY A	PPLICANT	First Named Inventor	Zailin Yu		
	# 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			Art Unit	1646		
(Use as many sheets as necessary)			necessary)	Examiner Name	Prema M. Mertz		
Sheet	1	of	1	Attorney Docket Number	ZYU-0603	7	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	· · · · ·
examiner Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	ARGOS, "An investigation of Oligopeptides Linking Domains in Protein Tertiary Structures and Possible Candidates for General Gene Fusion", J. Mol. Biol. 211:943-958, 1990.	
	2	Robinson et al, "Optimixing the Stability of Single-Chain Proteins by Linker Length and Composition mutagenesis", Proc. Natl. Acad. Sci. USA 95:5929-5934, 1998	
	3	Maeda et al, "Engineering of Functional Chimeric Protein G-Vargula lucifease*, Anal. Biochem. 249:147-152, 1997.	
	4	Layton et al, "Identification of a Functional Domain of Human Granulocyte Colonly-Stimulating Factor Using Neutralizing Monoclonal Antibodies", J. Biol. Chem., vol. 266, No. 35, , pp. 23915–23823, 1991.	
	5	Ball et al. "Improving the Oral Efficacy of Recombinant Granulocyte Colony-Stimulating Factor and Transferrin Fusion Protein by Spacer Optimization", Pharmaceutical Research, Vol. 23, No. 9, September 2008	
·, ····			

Examiner		Date	
Signature		Considered	
	Waster than the second of the	Drawling through a	Perion if and in applications and only

\*EXAMINER: Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submilling the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradamerk Office, P.O. Box 1450, Alexandre, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.